Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring

CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc's NTRA Signatera molecular residual disease (MRD) test.
An accompanying Billing and Coding Article specifies that serial testing with Signatera is now covered for Medicare patients being treated with immunotherapy, regardless of tumor type.
The final LCD for immunotherapy monitoring is the second Medicare LCD covering Signatera (the first was in early-stage colorectal cancer).
But it is the first covering Signatera for pan-cancer use in any patient where immunotherapy is indicated.
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
Price Action: NTRA shares are up 3.70% at $110.96 during the market session on the last check Thursday.